Saturn V Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Saturn V Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$60.5M	Sell	4,349,885 -146,602	-3%	-$2.06M	10.95%	2
2025 Q4	$54.3M	Sell	4,496,487 -108,391	-2%	-$1.47M	9.97%	2
2025 Q3	$62.6M	Buy	4,604,878 +1,344,308	+41%	+$12.7M	13.72%	2
2025 Q2	$20.9M	Buy	3,260,570 +834,134	+34%	+$4.06M	8.47%	3
2025 Q1	$8.59M	Buy	2,426,436 +1,537,363	+173%	+$5.47M	4.33%	11
2024 Q4	$3.36M	Buy	+889,073	New	+$4.18M	1.32%	19
2024 Q1	–	Sell	-1,099,268	Closed	-$16.2M	–	23
2023 Q4	$16.2M	Buy	1,099,268 +213,125	+24%	+$3.27M	6.19%	7
2023 Q3	$16.2M	Buy	+886,143	New	+$18.7M	6.79%	6

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Saturn V Capital Management's AMLX Position: Q1 2026 in Review

Saturn V Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 3.3% in Q1 2026, selling an estimated $2.06M and leaving 4,349,885 shares worth $60.5M. The position accounts for 10.95% of the portfolio, ranked #2.

Saturn V Capital Management first reported a position in AMLX in Q3 2023 and has held it in 8 quarters since. The position peaked at $62.6M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Saturn V Capital Management held 4,349,885 shares of Amylyx Pharmaceuticals worth $60.5M as of Q1 2026.
Saturn V Capital Management sold 146,602 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $2.06M.
Amylyx Pharmaceuticals made up 10.95% of Saturn V Capital Management's portfolio in Q1 2026, its #2 holding.
Saturn V Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
Saturn V Capital Management's Amylyx Pharmaceuticals position peaked at $62.6M in Q3 2025.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.